CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
=== Aisha Ali-Khan libel case === On 20 June 2016, Galloway lost a libel action brought by Aisha Ali-Khan, his assistant for six months in 2012. He had claimed that she had pursued a "dirty tricks" campaign against him and the Respect Party, and had slept at his house with her then-husband. The case was heard in the High Court. His counsel apologised on Galloway's behalf, and accepted that he had made "defamatory accusations". Ali-Khan will receive a "five-figure sum" in damages and her legal costs. As part of the settlement of their libel claim, both Galloway and Ali-Khan gave undertakings not to make any further public statement about the litigation or to defame each other. In 2018 Galloway brought an action that Ali-Khan had breached this undertaking 26 times, which Ali-Khan admitted, and in April 2018 the High Court imprisoned Ali-Khan for 12 weeks for contempt of court, describing her action as "deliberate, flagrant, persistent and inexcusable". Ali-Khan had been found guilty of contempt of court on a previous occasion. Previously, during 2017, Ali-Khan had filed a petition for Galloway's bankruptcy.
=== Transportation === Steel belts may be used to move the finished product or raw material or in parcel sorting systems, transporting of bottles, bulk loads, bricks, machinery parts and the like. Straight tracking, high abrasion resistance, and dynamic fatigue strength are crucial when transporting bulky material or unit load. Extremely high operating speeds cause a high number of load cycles and create severe operating conditions. Steel belts can be made to suit these extreme requirements.
Being South African, Player never played in the Ryder Cup in which American and European golfers compete against each other. Regarding the event, Player remarked, "The things I have seen in the Ryder Cup have disappointed me. You are hearing about hatred and war." He was no longer an eligible player when the Presidents Cup was established to give international players the opportunity to compete in a similar event, but he was non-playing captain of the International Team for the Presidents Cup in 2003, which was held on a course he designed, The Links at Fancourt, in George, South Africa. After 2003 ended in a tie, he was reappointed as captain for the 2005 Presidents Cup, and his team lost to the Americans 15.5 to 18.5. Both Player and Jack Nicklaus were appointed to captain their respective teams again in 2007 in Canada; the United States won.
Enzymes incur catalysis by binding more strongly to transition states than substrates and products. At the catalytic binding site, several different interactions may act upon the substrate. These range from electric catalysis, acid and base catalysis, covalent catalysis, and metal ion catalysis. These interactions decrease the activation energy of a chemical reaction by providing favorable interactions to stabilize the high energy molecule. Enzyme binding allows for closer proximity and exclusion of substances irrelevant to the reaction. Side reactions are also discouraged by this specific binding. Types of enzymes that can perform these actions include oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. For instance, the transferase hexokinase catalyzes the phosphorylation of glucose to make glucose-6-phosphate. Active site residues of hexokinase allow for stabilization of the glucose molecule in the active site and spur the onset of an alternative pathway of favorable interactions, decreasing the activation energy.
Sources: en.wikipedia.org
== Medical use == Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes. In the European Union, its use is limited to complementing insulin therapy. As of 2017 it is unclear if they affect a person's risk of death. It is provided in an autoinjector containing fourteen doses and is injected subcutaneously. Lixisenatide should not be used for people who have problems with stomach emptying. Lixisenatide delays emptying of the stomach, which may change how quickly other drugs that are taken by mouth take effect.
In October 2008, Russian journalist Irina Kuksenkova wrote in Moskovskij Komsomolets, "Russia fought in Ossetia for the strategically important territory. Now, even if NATO arrives in Georgia, we will have military bases in Java and Tskhinvali. This explains the fact that for 15 hours since the beginning of the war, our people did not undertake any action as if luring in Georgians, so then there would be something to present to the international community." In October 2008, Andrey Illarionov, former advisor to Vladimir Putin, in his interview with Echo of Moscow declared that it was suspicious that the evacuation of almost entire South Ossetian population began on 2 August and was finished before 8 August 2008, because this had not happened before during the previous escalations of tensions in the past 20 years. After the evacuation of the civilian population, the mobilization of volunteers started in the North Caucasus. Illarionov stated that the war is started with the mobilization. On 3 August 2008, the volunteers started to arrive in South Ossetia. Illarionov noted that all the volunteers were registered in the Military commissariats of the North Caucasus republics and were organized. On 4 August, several Russian special forces were deployed in South Ossetia. Illarionov also noted that since the late July the Ossetian media was reporting that the war was imminent and that Russian 58th Army would help them.
=== Exudates vs. transudates === There is an important distinction between transudates and exudates. Transudates are caused by disturbances of hydrostatic or colloid osmotic pressure, not by inflammation. They have a low protein content in comparison to exudates. Medical distinction between transudates and exudates is through the measurement of the specific gravity of extracted fluid. Specific gravity is used to measure the protein content of the fluid. The higher the specific gravity, the greater the likelihood of capillary permeability changes in relation to body cavities. For example, the specific gravity of the transudate is usually less than 1.012 and a protein content of less than 2 g/100 mL (2 g%). Rivalta test may be used to differentiate an exudate from a transudate. It is not clear if there is a distinction in the difference of transudates and exudates in plants.
Sources: en.wikipedia.org
== Chemistry == DkTx can be purified from the venom of the Chinese bird spider Ornithoctonus huwena using reversed-phase chromatography. DkTx is a cysteine-rich peptide; such peptides are difficult to synthesise because of their low folding efficiency. This is why structural and functional information about these peptides is limited. DkTx is a 75-amino-acid-peptide consisting of two independently folded head-to-tail ICK domains, which are linked together via a seven amino acid long linker peptide. This compact and rigid structure provides the toxin with a high affinity to bind to its target channel. The linker provides the separation of the two knots and allows them to dock to the channel binding sites concomitantly. The two ICK-motifs are referred to as K1 and K2, and each of them consists of six cysteine residues. For this reason, DkTx is part of the ICK peptide family; however its DNA sequence diverges from other ICK peptides, such as the vanillotoxins, huwentoxins or hanatoxin.
polycyclic structures (e.g. tetrodotoxin) compounds with a strong electron-withdrawing group attached to the acyl carbon (e.g. N,N-dimethyltrifluoroacetamide) compounds with donor groups that are poorly conjugated with the potential carbonyl group (e.g. cyclol) compounds with sulfur atoms bonded to the anomeric centre (e.g., S-acylated-1,8-naphthalenedithiol) These compounds were used to study the kinetics of tetrahedral intermediate decomposition into its respective carbonyl species, and to measure the IR, UV, and NMR spectra of the tetrahedral adduct.
== General references == Acheson, D. J. (1990), Elementary Fluid Dynamics, Oxford Applied Mathematics and Computing Science Series, Oxford University Press, ISBN 978-0-19-859679-0 Batchelor, G. K. (1967), An Introduction to Fluid Dynamics, Cambridge University Press, ISBN 978-0-521-66396-0 Currie, I. G. (1974), Fundamental Mechanics of Fluids, McGraw-Hill, ISBN 978-0-07-015000-3 V. Girault and P. A. Raviart. Finite Element Methods for Navier–Stokes Equations: Theory and Algorithms. Springer Series in Computational Mathematics. Springer-Verlag, 1986 Landau, L. D.; Lifshitz, E. M. (1987), Fluid mechanics, vol. Course of Theoretical Physics Volume 6 (2nd revised ed.), Pergamon Press, ISBN 978-0-08-033932-0, OCLC 15017127 Polyanin, A. D.; Kutepov, A. M.; Vyazmin, A. V.; Kazenin, D. A. (2002), Hydrodynamics, Mass and Heat Transfer in Chemical Engineering, Taylor & Francis, London, ISBN 978-0-415-27237-7 Rhyming, Inge L. (1991), Dynamique des fluides, Presses polytechniques et universitaires romandes Smits, Alexander J. (2014), A Physical Introduction to Fluid Mechanics, Wiley, ISBN 0-47-1253499 Temam, Roger (1984): Navier–Stokes Equations: Theory and Numerical Analysis, ACM Chelsea Publishing, ISBN 978-0-8218-2737-6 Milne-Thomson, L.M., C.B.E (1962), Theoretical Hydrodynamics, Macmillan & Company Limited Tartar, L (2006), An Introduction to Navier Stokes Equation and Oceanography, Springer ISBN 3-540-35743-2 Birkhoff, Garrett (1960), Hydrodynamics, Princeton University Press Campos, D.
The M80 Stiletto is equipped with four Caterpillar C32 1232 kW (1652 HP) engines yielding a top speed in excess of 60 knots (110 km/h) and a range of 500 nautical miles (900 km) when fully loaded. Alternatively, it may be fitted with jet drives for shallow-water operations and beaching. It has a topside flight deck for launching and retrieving unmanned aerial vehicles. Its rear ramp can launch and recover an 11-meter rigid-hull inflatable boat or autonomous underwater vehicle. It weighs 45 tons unloaded, light enough to be hoisted onto a cargo ship, yet it can carry a 20-ton payload. The craft is 88.6 feet (27.0 m) LOA, with a width of 40 feet (12.2 m) and a height of 18.5 feet (5.6 m) and a draft of 2.5 feet (0.8 m). The M80 Stiletto is the largest U.S. naval vessel using advanced carbon-fiber and epoxy composite materials, which yield a light yet strong hull. These craft are expected to cost between $6 and $10 million US Dollars each.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.